Flow cytometric assessment of platelet aspirin resistance using light scattering

Cytometry Part B - Clinical Cytometry

Volumn 74, Issue 2, 2008, Pages 110-117

  Won, Dong Il ^a,b   Yang, Dong Heon ^a   Kim, Dong Hyun ^a   Chae, Shung Chull ^a   Sun, Jang Soo ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

Author keywords

Aspirin; Flow cytometry; Platelet; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CITRIC ACID; CLOPIDOGREL; SODIUM CHLORIDE;

ANTICOAGULATION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEALTH CARE COST; HUMAN; HUMAN EXPERIMENT; LIGHT SCATTERING; NORMAL HUMAN; PRIORITY JOURNAL; THERAPY RESISTANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

ARACHIDONIC ACID; ASPIRIN; BIOLOGICAL ASSAY; BUFFERS; DRUG RESISTANCE; FLOW CYTOMETRY; HUMANS; LIGHT; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SCATTERING, RADIATION;

EID: 42549108977     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20377     Document Type: Article

References (24)

1. Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: Current concepts. Rev Cardiovasc Med 2004;5:156-163.
2. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;9:489-493.
3. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to low-dose aspirin and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-1007.
4. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-66.
5. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;17:1122-1126.
6. Minamino T, Kitakaze M, Sanada S, Aspirinnuama H, Kurotobi T, Koretsune Y, Fukunami M, Kuzuya T, Hoki N, Hori M. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: Role of nitric oxide. Circulation 1998;98:1721-1727.
7. Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003;111:165-170.
8. Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994;218:284-294.
9. Satoh K, Yatomi Y, Kubota F, Ozaki Y. Small aggregates of platelets can be detected sensitively by a flow cytometer equipped with an imaging device: Mechanisms of epinephrine-induced aggregation and antiplatelet effects of beraprost. Cytometry 2002;48:194-201.
10. Haubelt H, Simon M, Anders Ch, Hellstern P. Platelet function tests for monitoring of acetylsalicylic acid: Clinical significance in antiplatelet treatment Hamostaseologie 2004;24:196-202.
11. Eikelboom J, Feldman M, Mehta SR, Michelson AD, Oates JA, Topol E. Aspirin resistance and its implications in clinical practice. MedGenMed 2005;7:76.
12. Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975;228:1757-1765.
13. Matzdorff AC, Kuhnel G, Kemkes-Matthes B, Pralle H. Quantitative assessment of platelets, platelet microparticles, and platelet aggregates with flow cytometry. J Lab Clin Med 1998;131:507-517.
14. Rossi EC, Louis G. A time-dependent increase in the responsiveness of platelet-rich plasma to epinephrine. J Lab Clin Med 1975;85:300-306.
15. Newhouse P, Clark C. The variability of platelet aggregation. In: Triplett DA, editor. Platelet Function Laboratory Evaluation and Clinical Application, 1st ed. Chicago:American Society of Clinical Pathologists; 1978. pp 63-107.
16. Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987;70:647-651.
17. Tohgi H, Takahashi H, Watanabe K, Kuki H, ShirAspirinwa Y. Development of large platelet aggregates from small aggregates as determined by laser-light scattering: Effects of aggregant concentration and antiplatelet medication. Thromb Haemost 1996;75:838-843.
18. Fox SC, Sasae R, Janson S, May JA, Heptinstall S. Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry. Platelets 2004;15:85-93.
19. Eto K, Takeshita S, Ochiai M, Ozaki Y, Sato T, Isshiki T. Platelet aggregation in acute coronary syndromes: Use of a new aggregometer with laser light scattering to assess platelet aggregability. Cardiovasc Res 1998;40:223-229.
20. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: Areview of the evidence. J Am Coll Cardiol 2005;45:1157-1164.
21. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
22. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705-1709.
23. Antithrombotic Trialists. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
24. Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, Bray PF, Becker LC. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006;98:774-779.